CCL16

Across TCGA pan-cancer cohorts, CCL16 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCL16 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CCL16 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCL16 expression acts as an unfavorable survival marker.

LSCC, CCRCC, and LUAD are the cancer types where CCL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.903	1.000	.014	15	view →
CCRCC	OS	Quartile	II,III,IV	0.475	0.982	.001	9	view →
LUAD	DFS	Median	II,III,IV	0.655	0.942	.018	7	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCL16–LSCC (DFS)

Open the LSCC breakdown →